Last reviewed · How we verify
NCT03476993
Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis
Phase 2 trial testing BCD-085 in Liver Cirrhosis, Biliary in 9 participants. Terminated before completion.
1 July 2019
Quick facts
| Lead sponsor | Biocad |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 27 April 2018 |
| Primary completion | 1 July 2019 |
| Estimated completion | 1 July 2019 |
| Sites | 3 locations across Russia |
Drugs / interventions tested
- BCD-085 — full drug profile →
Conditions studied
- Liver Cirrhosis, Biliary — all drugs for Liver Cirrhosis, Biliary →
Sponsor
Biocad — full company profile →
Who can join
Adults 18 to 60, any sex, with Liver Cirrhosis, Biliary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
BCD-085 is an innovative drug, anti-interleukin-17 monoclonal antibody. The aim of the study is to evaluate the efficacy and safety of BCD-085 in patients with primary biliary cholangitis (PBC).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective.
Zwicky P, Unger S, Becher B. · · 2020 · cited 66× · PMID 31727781 · DOI 10.1084/jem.20191123 -
Novel Therapies for Managing Cholestasis.
Santiago P, Levy C. · · 2020 · cited 3× · PMID 32257119 · DOI 10.1002/cld.886
Verify or expand the search:
- PubMed search for NCT03476993
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BCD-085
Trials testing the same drug.
- NCT03598751 — Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis · Phase 3 · completed
- NCT03447704 — International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in · Phase 3 · completed
Other Biocad trials
Trials by the same sponsor.
- NCT07136389 — Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus · Phase 1 · recruiting
- NCT05974969 — A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subject · Phase 1 · completed
- NCT05802225 — Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer · Phase 3 · active not recruiting
- NCT05726630 — Clinical Study of Divozilimab in Patients With Systemic Scleroderma · Phase 3 · active not recruiting
- NCT05738993 — A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single I · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03476993 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Biocad
- Last refreshed: 11 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03476993.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing